Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19)
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease. The ANTARES Study
Sponsor: Janssen, LP
This PHASE2 trial investigates Extramedullary Plasmacytoma and Multiple Myeloma and is currently ongoing. Janssen, LP leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen, LP
- Stichting European Myeloma Network
For direct contact, visit the study record on ClinicalTrials.gov .